Table 5.

Association of androgen receptor gene CAG repeat length with prostate cancer among matched pairs nested in the Health Professionals Follow-up Study, 1993-1998

Length of androgen receptor gene CAG repeat*
Ptrend
≤1920-2122-23≥24
Total prostate cancer
    No. cases/controls80/83145/15187/100148/126
    OR (95% CI)0.84 (0.57-1.23)0.83 (0.60-1.15)0.76 (0.53-1.09)1.000.22
Regionally invasive or metastatic
    No. cases/controls4/813/177/618/11
    OR (95% CI)0.38 (0.09-1.50)0.54 (0.18-1.59)0.86 (0.23-3.26)1.000.11
Organ confined or minimal extraprostatic extension
    No. cases/controls67/65104/11070/79108/95
    OR (95% CI)0.92 (0.59-1.42)0.84 (0.57-1.23)0.80 (0.53-1.20)1.000.50
Gleason sum ≥ 7
    No. cases/controls26/3045/4432/2648/51
    OR (95% CI)0.88 (0.45-1.74)1.08 (0.62-1.87)1.31 (0.69-2.48)1.000.96
Gleason sum < 7
    No. cases44/3775/8343/6175/56
    OR (95% CI)0.92 (0.53-1.61)0.67 (0.41-1.10)0.55 (0.33-0.91)1.000.34
  • NOTE: Matched on age, time of day and year of blood draw, and PSA test before blood draw.

  • * Medians were 19, 21, 22, and 25 CAG repeats.

  • Reference group.